90.50

0.63% -0.57

After Hours: 90.50

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $90.50, with a volume of 12.69M. It is down -0.63% in the last 24 hours and up +7.33% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Previous Close:

$91.07

Open:

$90.54

24h Volume:

12.69M

Relative Volume:

1.01

Market Cap:

$157.63B

Revenue:

$45.13B

Net Income/Loss:

$6.28B

P/E Ratio:

25.21

EPS:

3.5895

Net Cash Flow:

$7.38B

1W Performance:

+3.10%

1M Performance:

+7.33%

6M Performance:

-25.87%

1Y Performance:

-32.25%

1-Day Range:

$90.23

$91.34

1-Week Range:

$85.89

$92.73

52-Week Range:

$81.97

$139.06

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1100)

Industry

Medical Devices (141)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

115,000

Twitter

@AbbottNews

Next Earnings Date

2026-07-16

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	90.50	158.63B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	301.53	117.18B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	80.69	104.85B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	48.70	72.16B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	85.85	49.50B	6.30B	1.07B	1.09B	1.8406

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-22-26	Downgrade	Daiwa Securities	Outperform → Neutral
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

Jun 08, 2026

Richard W. Allen Sells Shares in Abbott Laboratories, Ameriprise Financial and More - Investing.com Nigeria

Jun 08, 2026

Abbott Laboratories, maker of Similac baby formula, sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com

Jun 08, 2026

Governor Abbott, Secretary Rollins Update Texans On Screwworm Response At Kerrville Lab - Office of the Texas Governor (.gov)

Jun 08, 2026

Abbott's Healthy Food Rx Program Shows Promising Results for Dia - GuruFocus

Jun 08, 2026

Is It Time To Revisit Abbott Laboratories (ABT) After This Year’s Share Price Slump? - Yahoo Finance

Jun 08, 2026

Can Beyond Meat's Pivot to Protein Drinks Change the Investment Thesis? - The Motley Fool

Jun 08, 2026

Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock - insidermonkey.com

Jun 08, 2026

LIVE: Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KLBK

Jun 08, 2026

Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KXAN Austin

Jun 08, 2026

Food boxes and coaches tied to better diabetes health, less food insecurity - Stock Titan

Jun 08, 2026